COMMUNIQUÉS West-GlobeNewswire

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
19/03/2024
Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x10 14 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained improvement across key [...]
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
19/03/2024
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ [...]
Longeveron Announces 1-for-10 Reverse Stock Split
19/03/2024
MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today [...]
HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2024 Financial Results
19/03/2024
Highlights of the fiscal year include: Revenue of $999.6 million, an increase of 16% compared to $861.7 million in FY23. Net income of $55.7 million, compared to net loss of $26.1 million in FY23, with non-GAAP net [...]
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
19/03/2024
CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets [...]
SAFE - Tirage d’une tranche de 390 OCEANE par Global Corporate Finance Opportunities 20 - Erratum au communiqué de presse du 11 mars 2024
19/03/2024
Avertissement : La société SAFE SA a mis en place un financement sous forme d’obligations convertibles en actions nouvelles ou existantes (OCEANE) avec le fonds Global Corporate Finance Opportunities 20 (« GCFO 20 »), [...]
CARBOGEN AMCIS announces successful ANVISA audit of its facility in China
19/03/2024
BUBENDORF, Switzerland, March 19, 2024 (GLOBE NEWSWIRE) -- Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces the [...]
Impressive $3.3M investment in Basic Mental Health Research
19/03/2024
Three recipients, along with their dedicated research teams, receive $1.1 million each to advance our understanding of mental health conditions at a fundamental level MONTREAL, March 19, 2024 (GLOBE NEWSWIRE) -- In [...]
Investissement important de 3,3 M$ dans la recherche fondamentale en santé mentale
19/03/2024
Trois lauréats et leurs équipes de recherche attitrées reçoivent chacun 1,1 million de dollars pour faire progresser notre compréhension des problèmes de santé mentale à un niveau fondamental. MONTRÉAL, 19 mars 2024 ( [...]
Disclosure notification from Mawer Investment Management Ltd.
19/03/2024
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 19 March 2024 – 6PM CET Disclosure notification from Mawer Investment Management Ltd. On 18 March 2024, Fagron received a notification pursuant to [...]
Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2023
19/03/2024
Public release of Virbac Consolidated Accounts at 31 December 2023. The Group released its 2023 Consolidated Accounts. The document is available on the corporate website, at corporate.virbac.com, under “Investors”, “ [...]
Virbac: Communiqué de mise à disposition des comptes consolidés au 31 décembre 2023
19/03/2024
Communiqué de mise à disposition des comptes consolidés au 31 décembre 2023. Le Groupe annonce avoir mis à la disposition du public ses comptes consolidés au 31 décembre 2023 sur le site internet du Groupe, à l’adresse [...]
VIRBAC: 2023 ANNUAL RESULTS
19/03/2024
Revenue up 4.9%, enabling market share gains despite difficulties in 2023 2023 operating profitability 1 at an all-time high of 23.2% of revenue Up 0.4 points compared to 2022 Strong momentum expected in 2024 Expected [...]
Virbac : Résultats annuels 2023
19/03/2024
Chiffre d’affaires en progression de 4,9% permettant des gains de parts de marché malgré des difficultés en 2023 Rentabilité opérationnelle 1 2023 à un niveau historique de 23,2% du chiffre d’affaires En progression de [...]
Zealand Pharma major shareholder announcement: Polar Capital
19/03/2024
Company announcement – No. 16 / 2024 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 19 March 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen- [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
19/03/2024
Company announcement – No. 15 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March [...]
NMDP Receives Record-Breaking $5 Million Philanthropic Gift
19/03/2024
The Moore family’s donation accelerates NMDP’s lifesaving mission MINNEAPOLIS, March 19, 2024 (GLOBE NEWSWIRE) -- NMDP SM , formerly Be The Match, recently received a $5 million gift from the Moore family – the largest [...]
DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome
19/03/2024
FARMINGDALE, N.Y., March 19, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many poorly treated diseases [...]
BettorEdge to Offer Responsible Gaming Resources and Connections to Problem Gambling Care through Birches Health Partnership
19/03/2024
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- BettorEdge, a national online sports betting exchange and social platform, has joined forces with Birches Health to provide its audience with new Responsible Gaming education [...]

Pages